TL Biopharmaceutical

TL Biopharmaceutical is a Swiss-based biotechnology company dedicated to the development of biosimilar versions of leading monoclonal antibody products. Headquartered in Zug, the company focuses on therapeutic areas such as oncology and autoimmune diseases, with a pipeline that includes biosimilars for blockbuster drugs like Herceptin, Rituxan, and Avastin. TL Biopharmaceutical utilizes a partnership-driven model, collaborating with global manufacturing and clinical research organizations to advance its candidates through regulatory pathways. The company's mission is to provide cost-effective alternatives to high-priced biologic medicines, thereby improving patient access to life-saving treatments globally.